Doç. Dr. Elif Şenocak Taşçı

• Neoplasms 3 publications
  Source: OpenAlex / PubMed MeSHView publications
• Adenocarcinoma 2 publications
• Stomach Neoplasms 2 publications
• Osteoporosis 2 publications
• Colonic Neoplasms 2 publications

Medical areas of interest the doctor lists on their own profile on the institution’s website. Source: acibadem.com.tr.

Experience

• 2023 - 2025Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi / Tıbbı Onkoloji Uzmanıacibadem.com.tr
• 2020Acıbadem Sağlık Grubuacibadem.com.tr
• 2019 - 2020Haydarpaşa Numune Eğitim ve Araştırma Hastanesi / İç Hastalıkları Uzmanıacibadem.com.tr

Education

• 2023Acıbadem Mehmet Ali Aydınlar Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji, Üst Uzmanlıkacibadem.com.tr
• 2017Düzce Üniversitesi Tıp Fakültesi, İç Hastalıkları, Uzmanlıkacibadem.com.tr
• 2012Yeditepe Üniversitesi Tıp Fakültesi, Üniversiteacibadem.com.tr
• 2006Robert Kolej, Digeracibadem.com.tr

• SpecialtyMedical Oncologyacibadem.com.trFrom source
• InstitutionAcıbadem Atakent Hastanesiacibadem.com.trFrom source
• Area of workNeoplasmsExtracted from 3 publications · Model version —From source
• Publications39 publicationsOpenAlexFrom source
• Last synchronised4 November 2026 21:12https://www.acibadem.com.tr/doktor/elif-senocak-tasci/acibadem.com.tr

1. Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study

   Discover Oncology, 2026

   DOI 10.1007/s12672-026-04842-3 PMID 41870760 Open-access full textSource: OpenAlex

2. Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 1: Locoregional Therapy, Pathology, Radiology

   European Journal of Breast Health, 2026

   DOI 10.4274/ejbh.galenos.2026.2025-10-1 PMID 41873792 Open-access full textSource: OpenAlex

3. Evaluation of clinicopathological features and prognosis of patients with small cell carcinoma of gastrointestinal system origin.

   Journal of Clinical Oncology, 2026

   DOI 10.1200/jco.2026.44.16_suppl.e16481 Source: OpenAlex

4. HPV-positive oropharyngeal squamous cell carcinoma: risk-adapted treatment strategies and biomarker-guided individualization

   Oral Oncology, 2026

   DOI 10.1016/j.oraloncology.2026.108005 PMID 42107222 Source: OpenAlex

5. Risk-adaptive management of stage III NSCLC in the perioperative immunotherapy era: a critical synthesis and clinical framework

   Frontiers in Oncology, 2026

   DOI 10.3389/fonc.2026.1897546 PMID 42775057 Open-access full textSource: OpenAlex

6. Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study

   Scientific Reports, 2025

   DOI 10.1038/s41598-025-09707-3 PMID 40653542 5 citations (Europe PMC) Open-access full textSource: OpenAlex

7. A multi-center case-control study on osteoporosis risk in cancer patients receiving chemotherapy.

   Journal of Clinical Oncology, 2025

   DOI 10.1200/jco.2025.43.16_suppl.12033 Source: OpenAlex

8. Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 2: Systemic Treatment

   European Journal of Breast Health, 2025

   DOI 10.4274/ejbh.galenos.2025.2025-10-2 PMID 41447641 Open-access full textSource: OpenAlex

9. A multicenter prospective matched comparative study on osteoporosis risk in cancer patients receiving chemotherapy

   Supportive Care in Cancer, 2025

   DOI 10.1007/s00520-025-09973-x PMID 41225034 1 citation (Europe PMC) Source: OpenAlex

10. Real‑world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group retrospective study

    Molecular and Clinical Oncology, 2025

    DOI 10.3892/mco.2025.2846 PMID 40297501 Open-access full textSource: OpenAlex